Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy

Anti-angiogenic therapies for cancer such as VEGF neutralizing antibody bevacizumab have limited durability. While mechanisms of resistance remain undefined, it is likely that acquired resistance to anti-angiogenic therapy will involve alterations of the tumor microenvironment. We confirmed increase...

Descripción completa

Detalles Bibliográficos
Autores principales: Castro, B A, Flanigan, P, Jahangiri, A, Hoffman, D, Chen, W, Kuang, R, De Lay, M, Yagnik, G, Wagner, J R, Mascharak, S, Sidorov, M, Shrivastav, S, Kohanbash, G, Okada, H, Aghi, M K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491354/
https://www.ncbi.nlm.nih.gov/pubmed/28218903
http://dx.doi.org/10.1038/onc.2017.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491354/
https://www.ncbi.nlm.nih.gov/pubmed/28218903
http://dx.doi.org/10.1038/onc.2017.1

Ejemplares similares